ArticlePharmaceutics2020

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.

Ayman Abouzayed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.